Skip to main content
. 2018 Nov 22;10(12):464. doi: 10.3390/cancers10120464

Figure 7.

Figure 7

Recombinant ISG15 protein suppressed tumor progression in tumor-bearing animals. (A) Administration of 1 mg/kg recombinant ISG15 twice weekly suppress tumor progression in ID8 tumor-bearing C57BL/6 mice. A significant decrease in tumor weight in ISG15 treated mice was observed when compared to PBS treated mice. (B) Immunolocalization of CD8+ cells in tissue samples harvested from the ISG15 treated and the control mice demonstrated a significant increase in intraepithelial CD8+ lymphocyte density in ISG15 treated mice than in control mice. (Bar = 100 μm).